ROLE SUMMARY The International Commercial Office will establish a commercial operating model for Brepocitinib, a TYK2/JAK1 inhibitor. Our initial indication (pending regulatory approval) is focused on dermatomyositis, a rare chronic systemic autoimmune disease characterized by muscle weakness and